MENLO PARK, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc., (Nasdaq:PACB) a pioneer and leader in long-read sequencing using its Single Molecule, Real-Time (SMRT®) Technology, today announced that its technology will be featured in at least 46 podium presentations and 42 posters at the International Plant & Animal Genome (PAG) XXIV Conference taking place January 9-13 in San Diego. These projects demonstrate the unparalleled utility of long-read sequencing for reference-grade de novo assemblies as well as gene identification in large, complex genomes.
PacBio will host a workshop on January 12 at 1:30 p.m. with speakers from the company, the San Diego Zoo Institute for Conservation Research, the USDA and Cold Spring Harbor Laboratory, The Roslin Institute, and King Abdullah University of Science and Technology. Topics will cover both conservation genomics and agrigenomics, with high-quality genome assemblies presented for a number of plant and animal species, including maize and quinoa, as well as an endangered bird and a domesticated pig breed. PacBio speakers will report on SMRT Sequencing technology updates and an initiative for expedited, open-access genome studies.
Immediately following PAG, PacBio will hold a SMRT Informatics Developers Conference at the same location from 12:00 p.m. to 5:30 p.m. on January 13. The event will focus on de novo genome assembly tools and analysis solutions for Iso-Seq™ data. Sergey Koren from the National Human Genome Research Institute will give the meeting’s keynote talk. Interested parties can learn more about this free event here.
“Each year we have seen a remarkable increase in the number of SMRT Sequencing projects presented at PAG,” said Kevin Corcoran, Senior Vice President, Market Development for Pacific Biosciences. “The plant and animal scientific community has an impressive track record of deploying our long-read sequencing system to characterize complex genomes and discover novel genes in organisms that have been nearly impossible to represent accurately with other technologies.”
More information about PacBio’s activities at the PAG conference is available here. A full list of PacBio-related research being presented at PAG is available here. Attendees can also see the new Sequel™ System in booth #421.
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers sequencing systems to help scientists resolve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. Pacific Biosciences’ technology provides the industry’s highest consensus accuracy over the longest read lengths in combination with the ability to detect real-time kinetic information. PacBio sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to future uses, quality or performance of, or benefits of using, products or technologies, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Contacts: Media: Nicole Litchfield 415.793.6468 nicole@bioscribe.com Investors: Trevin Rard 650.521.8450 ir@pacificbiosciences.com
